Fresenius Group welcomes the opportunity to contribute to this call for evidence, as the revision of the Public Procurement Directive 2014/24/EU (PPD) provides a framework for the public procurement of medicines (PPM). We are operating in a highly regulated pricing framework, which does not allow for the adjustment of prices to increasing costs (e.g. energy, transport inflation).
FRE
Fresenius
Company · Germany · EU Transparency Register 047428334069-39
3
positions filed
in the 326 files tracked
3
legislative files
of 326 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #280 by legislative files engaged — a count of participation, not a measure of influence.
1.5
declared lobbying FTE
self-declared
€300K+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2019
in the register since
Declares membership of
- Fresenius SE & Co.KGaA and its consolidated subsidiaries are represented in a large number of associations worldwide.
- Memberships of Fresenius SE & Co.KGaA in organisations that would be relevant for the register are as follows:
- MedTech Europe →
- Pharma Deutschland e. V. →
- Bundesverband Medizintechnologie e. V. (BVmed)
- Verband der Chemischen Industrie e.V. (VCI)
- Blood Transfusion Association →
- German Health Alliance (GHA)
- Deutsches Institut für Normung e. V. (DIN)
- Medicines for Europe →
- Specialised Nutrition Europe
- Medical Nutrition International Industry Association
- and 1 more
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Fresenius SE & Co.KGaA (FSE)
- Head office
- Bad Homburg, Germany
- EU office
- Brüssel
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Fresenius in PolicySpeak: request access →
Work at Fresenius? so we know who speaks for it.
Their record over time
Fresenius filed 3 positions between 6 Mar 2025 and 5 Aug 2026, across 3 of the 326 legislative files tracked here, attaching a full position paper 2 times.
2025 · 1 filed2026 · 2 filed
What they argued
Fresenius welcomes the European Commission's proposal for a Biotech Act as an important step towards strengthening Europe's biotechnology and biomanufacturing ecosystem. The proposal rightly recognises biosimilars as a strategic biotechnology industry.
The proposed regulatory frameworks (CSA2 and Digital Omnibus) aim to create stronger alignment across EU cyber regulation and to reduce duplicative administrative burdens, particularly around incident reporting and certification. At the same time, they expand requirements in key areas such as ICT supply chains, cybersecurity certification, and EU-level governance (ENISA).
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- Danish Industry · 3 files in common
- Danish Chamber of Commerce · 3 files in common
- MedTech Europe · 3 files in common
- IDEE ECONOMICHE www.idee-economiche.it · 2 files in common
- Cefic · 2 files in common
Showing 5 of 45.
Is this your organization?
Everything on this page comes from Fresenius’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.